Clinique Victor Hugo

The medical center is at the forefront of research in head and neck cancer, focusing on innovative treatment combinations to enhance patient outcomes. The ongoing study investigates the efficacy of combining radiotherapy with cetuximab and Xevinapant, a promising study drug, compared to the traditional combination with a placebo.

• Radiotherapy and Cetuximab Combination
• Xevinapant as a Study Drug
• Locally Advanced Squamous Cell Carcinoma

This research aims to demonstrate significant improvements in progression-free survival (PFS), evaluated by an independent review committee, offering new hope for patients with locally advanced squamous cell carcinoma of the head and neck.

Specializing in prostate cancer, the center is conducting pivotal research on treatment strategies for metastatic hormone-sensitive prostate cancer. The study explores the potential benefits of adding abemaciclib to the standard regimen of abiraterone and prednisone.

• Abemaciclib and Abiraterone Combination
• Hormonal Treatment Response
• High-Risk Metastatic Cases

The primary objective is to assess improvements in radiographic progression-free survival (rPFS), providing critical insights into more effective treatment protocols for high-risk patients.